Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Shisa family member 3 (SHISA3)
- Target
- SHISA3
- Molecular classification
- Transmembrane adaptor protein, Shisa family member, Single-pass membrane protein, Modulator of WNT and FGF signaling
01
Overview
Shisa family member 3 (SHISA3) encodes a single-pass transmembrane adaptor protein of the Shisa family that regulates WNT and FGF signaling by blocking the maturation and cell surface transport of their receptors. SHISA3 functions primarily as a tumor suppressor by accelerating β-catenin degradation, thus antagonizing the WNT pathway. Loss or epigenetic silencing of SHISA3 (often via promoter hypermethylation) is associated with enhanced tumorigenesis, cancer cell proliferation, migration, metastasis, and poor clinical outcomes in various cancers. Restoration of SHISA3 expression can inhibit cancer cell growth and migration, indicating its promise as a diagnostic, prognostic, and predictive biomarker in oncology
- Other names
- Protein shisa-3 homologhShisa3shisa homolog 3HSHISA3SHSA3_HUMAN
02
Mechanism of action
For demethylating agents: reactivation of SHISA3 by demethylation of its promoter; resulting in restored tumor suppression activity
03
Biological functions
Modulation of WNT signaling (by antagonizing β-catenin)Modulation of FGF signalingRegulation of cell proliferationInhibition of cell migrationSuppression of tumorigenesis and metastasis
04
Disease associations
Cancer (frequently silenced or inactivated by promoter hypermethylation in breast, lung, laryngeal, nasopharyngeal, and colorectal cancers)Tumor progression and metastasisDynamics of therapy resistance (e.g., reversal of resistance to EGFR tyrosine kinase inhibitors)
05
Safety considerations
No specific molecule-related pharmacological safety concerns known; general concerns may apply for epigenetic therapies.
06
Interacting drugs
5-aza-2’-deoxycytidine (decitabine)
07
Biomarkers
SHISA3 promoter hypermethylation as a diagnostic and prognostic biomarker in breast, lung, and other cancersCorrelation of SHISA3 expression with response to therapies (e.g., lenalidomide efficacy in chronic lymphocytic leukemia)
Beyond the preview
Go deeper on Shisa family member 3 (SHISA3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shisa family member 3 (SHISA3).